Ireland - English - HPRA (Health Products Regulatory Authority)

bayer plc - mezlocillin - 0.5 g/100ml

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer plc - mezlocillin - 1.0 g/100ml

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer plc - mezlocillin - 2.0 g/100ml

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer plc - mezlocillin - 5.0 g/100ml

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cilastatin sodium 530.7mg equivalent to 500 mg cilastatin; imipenem monohydrate 530.1mg equivalent to 500 mg imipenem - powder for injection - 500mg/500mg - active: cilastatin sodium 530.7mg equivalent to 500 mg cilastatin imipenem monohydrate 530.1mg equivalent to 500 mg imipenem excipient: sodium bicarbonate - indicated for the treatment of the following infections due to susceptible organisms: · intra-abdominal infections · lower respiratory tract infections · gynaecological infections · septicaemia · genitourinary tract infections · bone and joint infections · skin and soft tissue infections · endocarditis indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. the majority of these mixed infections are associated with contamination by faecal flora or flora originating from the vagina, skin and mouth. in these mixed infections, bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, ephalosporins and penicillins. however, bacteroides fragilis is usually susceptible to imipenem and cilastatin combination. imipenem and cilastatin combination has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-g, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment imipenem and cilastatin. imipenem+cilastatin rbx is not indicated for the treatment of meningitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - cefotaxime sodium - powder for solution for injection/infusion - 500 milligram(s) - third-generation cephalosporins; cefotaxime

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - cefotaxime sodium - powder for solution for injection/infusion - 1 gram(s) - third-generation cephalosporins; cefotaxime

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - cefotaxime sodium - powder for solution for injection/infusion - 2 gram(s) - third-generation cephalosporins; cefotaxime

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - cilastatin sodium eqv cilastatin; imipenem - injection, powder, for solution - 500 mg/vial - cilastatin sodium eqv cilastatin 500 mg/vial; imipenem 500 mg/vial

Malta - English - Medicines Authority

macarthys laboratories limited bampton road, harold hill, romford essex, rm3 8ug, united kingdom - pethidine hydrochloride - solution for injection - pethidine hydrochloride 5 % (w/v) - analgesics